Blog

Neuropsychiatric side-effects lead only 1 in 40 to drop dolutegravir, French study shows

[From aidsmap, August 22, 2018]

“A large French study of people taking HIV treatment that contained an integrase inhibitor found that approximately one person in forty who started treatment with dolutegravir stopped taking the drug due to neuropsychiatric side-effects, a significantly higher rate than observed in people taking either elvitegravir or raltegravir, a poster presentation at last month’s 22nd International AIDS Conference (AIDS 2018) showed.”

For more, click here.